No Data
No Data
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $24
Hims & Hers Health: Balancing Strong Performance With Regulatory Uncertainty – Hold Rating Maintained
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Hims & Hers Health (HIMS) and MannKind (MNKD)
Hims & Hers Health Options Spot-On: On November 5th, 162.7K Contracts Were Traded, With 342.86K Open Interest
Hims & Hers Stock Rises on Earnings and Planned Generic Version of Novo Nordisk Diabetes Drug -- Barrons.com
What's Going On With Hims & Hers Health Stock Tuesday?
No Data
No Data
102844729 : Now make it an ETF